Krystal Biotech, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Krystal Biotech (KRYS) shares rose 12% since its last earnings report, outperforming the S&P 500. The company reported Q2 2026 EPS of $1.79, beating estimates, with revenues of $119.2M, up 24% YoY. Vyjuvek sales drove growth, and the company maintained its 2026 guidance. Analysts have upwardly revised estimates, but the stock's momentum and value scores are low.
Investing.com reported major US insider trades disclosed Friday. Buys: PAL director Rohit Lal bought $272.5k; OTLK director/10% owner Ghiath Sukhtian bought about 2.5M shares and warrants for ~$2.5M; CLPR director Sam Levinson bought ~$488.8k; OPFI CEO Todd Schwartz bought ~$144k; OPEN CEO Kasra Nejatian bought ~$100k. Sells: CRWV 10% owner Magnetar sold ~$231.6M then ~$213.8M; ANET CEO Ullal trust sales ~$119.3M; SEPN RA Capital sold $63.45M; KRYS director Rossi sold ~$8.23M.
Krystal Biotech director Dino A. Rossi sold about 25,000 shares for roughly $8.23m on Aug. 14, 2026, per an SEC Form 4, at weighted average prices of $325.60 to $333.23. He also gifted 3,691 shares to a donor-advised fund. Krystal Biotech reported Q2 diluted EPS of $1.79 (vs $1.70 est.) and revenue of $119.2m (vs $122.3m est.).
Over the past 7 days, alphai's AI scored 1 news story mentioning KRYS (Krystal Biotech, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent KRYS coverage spans financial news, earnings and market movers.
In the last 30 days, KRYS insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($8.2M). The most active reporter was ROSSI DINO A with 8 filings.
Price gain reflects momentum from prior earnings; no fresh catalyst.
Director selling after a strong one-year gain may be interpreted as profit-taking rather than a thesis change.
The Form 4 discloses insider selling by a director, which can pressure sentiment but is not a fundamental change by itself.
Insider open-market selling by a director is a modest, near-term sentiment signal but not typically a fundamental catalyst by itself.
Initiation can drive speculative biotech interest, especially if investors focus on platform expansion optionality.
alphai scores every news story that mentions KRYS with an AI model for sentiment and relevance, and aggregates insider trades from Krystal Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Krystal Biotech (KRYS) shares rose 12% since its last earnings report, outperforming the S&P 500. The company reported Q2 2026 EPS of $1.79, beating estimates, with revenues of $119.2M, up 24% YoY. Vyjuvek sales drove growth, and the company maintained its 2026 guidance. Analysts have upwardly revised estimates, but the stock's momentum and value scores are low.
2 min readInvesting.com reported major US insider trades disclosed Friday. Buys: PAL director Rohit Lal bought $272.5k; OTLK director/10% owner Ghiath Sukhtian bought about 2.5M shares and warrants for ~$2.5M; CLPR director Sam Levinson bought ~$488.8k; OPFI CEO Todd Schwartz bought ~$144k; OPEN CEO Kasra Nejatian bought ~$100k. Sells: CRWV 10% owner Magnetar sold ~$231.6M then ~$213.8M; ANET CEO Ullal trust sales ~$119.3M; SEPN RA Capital sold $63.45M; KRYS director Rossi sold ~$8.23M.
7 min readKrystal Biotech director Dino A. Rossi sold about 25,000 shares for roughly $8.23m on Aug. 14, 2026, per an SEC Form 4, at weighted average prices of $325.60 to $333.23. He also gifted 3,691 shares to a donor-advised fund. Krystal Biotech reported Q2 diluted EPS of $1.79 (vs $1.70 est.) and revenue of $119.2m (vs $122.3m est.).
3 min readROSSI DINO A sold 25,000 shares of Krystal Biotech, Inc. (KRYS) at an average of $329.12 ($325.60–$333.23, $8.23M total) across 8 trades on 2026-08-14.
2 min readAnalyst notes on Friday included KeyBanc reiterating Apple as underweight, citing iPhone 17 carrier survey data slightly positive but with iPhone 18 price uncertainty. Bernstein upgraded Wayfair to Outperform, raising its PT to $125. Morgan Stanley reiterated Nvidia as overweight. Other calls covered Fox, Intuitive Machines, Cinemark, SanDisk, Energy Fuels, Digital Realty, SpaceX, Dell, Micron, and T-Mobile.
6 min readThe article reports Friday’s Wall Street analyst research calls after cooler-than-expected CPI and PPI helped lift the S&P 500 to a record and Nasdaq up 0.81%. It cites upgrades, downgrades, and initiations including JPMorgan upgrading FoxA to Overweight with an $82 target and RBC initiating Krystal Biotech (KRYS) at $400. It also lists multiple other price targets across stocks.
3 min readEli Lilly (LLY) reported Q2 results that beat forecasts and raised 2026 GAAP revenue guidance to $85B-$87B. Q2 revenue rose 48% to $22.974B and net income rose 25% to $7.095B. Leerink raised its 12-month price target to $1,309. Krystal Biotech (KRYS) shares fell after a slight Vyjuvek revenue miss, though analysts cited strong patient growth.
6 min readSimply Wall St reports Krystal Biotech (KRYS) Q2 2026 results: net income rose to $54.77M from $38.33M, with basic EPS from continuing ops at $1.85 and diluted EPS at $1.79. First-half 2026 net income was $110.70M. The piece links profitability to VYJUVEK demand and concentration risk.
6 min readStocks settled sharply higher as Middle East tensions eased. The article cites a 66% chance of a +25 bp FOMC hike (Sept 15-16) and an 88% chance of an ECB +25 bp hike (Sept 10). WTI fell over 5%, lifting 10-year Treasuries and lowering yields. It also lists major movers including META (+6%), ORCL (+9%), and ATKR (+28%) after a $3.8B deal.
6 min readMarkets were mixed as investors priced a 63% chance of a 25 bp FOMC hike on Sept. 15-16. U.S. 10-year yields fell to 4.688% and German bunds and UK gilts moved lower. Airline and cruise stocks rose as WTI dropped over 6%. Software gained, while semiconductors and energy fell. Notable movers included ATKR (+28%) on a $3.8B Prysmian deal and CNH (+16%) raising EPS guidance.
7 min read
